Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PMC 309

Next Previous
Drug Profile

PMC 309

Alternative Names: Anti-VISTA antibody - PharmAbcine; PMC-309

Latest Information Update: 01 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PharmAbcine
  • Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; VISTA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Diabetic retinopathy; Wet age-related macular degeneration

Most Recent Events

  • 01 Aug 2024 Preclinical trials in Diabetic retinopathy in South Korea (unspecified route) before August 2024 (PharmAbcine pipeline, August 2024)
  • 01 Aug 2024 Preclinical trials in Wet age-related macular degeneration in South Korea (unspecified route) before August 2024 (PharmAbcine pipeline, August 2024)
  • 23 Jan 2024 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater, Combination therapy) in Australia (IV) (NCT05957081)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top